MannKind | MNKD - Pre Tax Profit


MannKind reported $-16.37M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Adma Biologics USD 61.59M 14.07M Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Insmed USD -162.1M 164.84M Mar/2026
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
MacroGenics USD -14.93M 31.75M Dec/2025
MannKind USD -16.37M 4.56M Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Novavax USD 17.9M 220.94M Dec/2025
Novo Nordisk DKK 25.52B 8.29B Sep/2025
Pfizer USD 5.18B 6.82B Mar/2026
Sanofi EUR -1.16B 5.5B Dec/2025
Xencor USD -128.64M 124.37M Mar/2026